To address this knowledge gap, a diverse set of potent lysyl-tRNA synthetase inhibitors were profiled to identify optimal physicochemical and pharmacokinetic properties required for efficacy in a chronic mouse model of infection. The gene discussed is KARS1; the disease is infection.